viewSummit Therapeutics PLC

Summit Therapeutics sees a bright future for its antibiotics programmes

Glyn Edwards, chief executive of Summit Therapeutics PLC (LON:SUMM), spoke to Proactive's Andrew Scott following the disappointing results from the mid-stage study of their Duchenne muscular dystrophy drug.

Edwards says one of the key focuses going forward is Ridinilazole, Summit’s lead candidate, which is due to enter phase III trials in the first quarter of 2019.

Using their Discuva drug discovery platform, the company's also identified two possible compounds for gonorrhoea – a sexually transmitted infection which affects an estimated 78mln people every year.

Quick facts: Summit Therapeutics PLC

Price: 22 GBX

Market: AIM
Market Cap: £35.31 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Summit Therapeutics PLC named herein, including the promotion by the Company of Summit Therapeutics PLC in any Content on the Site, the Company...



Summit Therapeutics' Glyn Edwards talks US$50mln backing and ridinilazole...

Summit Therapeutics PLC's (LON:SUMM, NASDAQ:SMMT) CEO Glyn Edwards sat down with Proactive London's Andrew Scott following the news of a US$50mln funding deal with biotech billionaire Bob Duggan. The investment will help get the company’s next-generation antibiotic through phase III clinical...

5 hours, 41 minutes ago

2 min read